Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT05855083 | Efficacy and Safety Study of Narsoplimab in Pediatric Patients With High-Risk Hematopoietic Stem Cell Transplant TMA | PHASE2 | RECRUITING | 18 | — | — | May 1, 2023 | Dec 1, 2025 | Mar 25, 2025 | 16 | United States, Germany +3 |
Percentage of patients alive at 100 days following the diagnosis of high-risk HSCT-TMA
| Arm | Type | Description |
|---|---|---|
| Narsoplimab single arm-treatment | EXPERIMENTAL | Narsoplimab 4 mg/kg |
| Name | Type | Description |
|---|---|---|
| Biological: narsoplimab | DRUG | Treatment with narsoplimab 4 mg/kg will be administered |
Inclusion Criteria: 1. Age at least 28 days and less than 18 years prior to informed consent (Visit 0). 2. Have informed consent from at least one parent or legal guardian as required by local law and regulation. Patient informed consent will be required if the patient has reached the local legal a...